Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval from the US Food and Drug Administration (FDA) to assess its Category 1 drug UBT251 in a Phase II study for the treatment of chronic kidney disease (CKD).
Drug Profile
UBT251 is a triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon (GCG) receptors. It is the first of its kind to be domestically synthesized in China. The drug has also been cleared for study in the same indication in China last month.-Fineline Info & Tech
Leave a Reply